Keywords
Research antibodies, experimental reproducibility, monoclonal antibody, polyclonal antibody, application, species reactivity
This article is included in the Antibody Validations gateway.
Research antibodies, experimental reproducibility, monoclonal antibody, polyclonal antibody, application, species reactivity
In producing the second version of our manuscript we followed suggestions from the reviewers and included more information and references regarding antibody validation. In addition, more emphasis on problems with batch-batch variability, the importance of knowing the antigen and a reference which shows good antibody reporting was added.We also added more emphasis on the fact that change is likely to require help from journals, specifically that they include antibody reporting guidelines in their instructions to authors.
See the authors' detailed response to the review by Simon Glerup
See the authors' detailed response to the review by John Colyer
See the authors' detailed response to the review by David Soll
Neuroscience, cancer research, regenerative medicine, infection and immunity, cell biology and cardiovascular research are just some of the fields in which research antibodies are commonly used. The sheer scale of their use is illustrated by huge sales, estimated to be worth in excess of $1.6 billion annually1. Despite, or perhaps because of this widespread use, it is common to hear dissatisfaction among research scientists about the quality of these antibodies2–4. The finger of blame is often pointed at the manufacturers, yet it is questionable whether scientists themselves are doing everything they can to help the situation; surely not all problems can be placed at the door of the antibody manufacturer. One example of scientists not helping themselves is in their reporting of antibody use. There are many cases of good practice (For example5) and detailed reporting, but all too frequently authors omit key details. These include the host species and code numbers, but even the source of the antibody may be left out. This makes it harder for reviewers to establish how well characterised the antibodies are and thus how reliable the data presented are likely to be. It also makes it more difficult for other researchers to accurately reproduce experiments.
Failure to report key information is not a new problem2,6, but recent developments have increased efforts to find a solution. In particular, experimental reproducibility has been thrust into the limelight by high profile cases. For example, a study of "landmark" cancer research papers found that scientific findings from only 11% of them could be repeated7. Taken at face value this is a shocking statistic and, in an attempt to try to improve experimental reproducibility, the Nature Publishing Group have recently introduced a reporting checklist for life science articles8. This checklist highlights research antibodies as a reagent type for which reporting could be improved. A key question is; what information to provide? In this commentary we consider what information authors should be including in their publications to help improve experimental reproducibility.
Publications need to report core information regarding the antibodies that were used. This should include the name of the antibody, the company/academic who supplied the antibody, the host species in which the antibody was raised and whether the antibody is monoclonal or polyclonal. In addition, the catalogue or clone number needs to be mentioned. The catalogue or clone number is commonly omitted from current publications, but is important as large antibody companies will often have multiple antibodies to the same target, a unique identifier is therefore essential to allow unambiguous identification of the antibody concerned. For this reason the first step in improving reporting should be to make it mandatory for authors to include core antibody information, including a code or clone number for the antibodies they use.
A second type of information that should be reported relates to experimental details. The application the antibody was used for is of central importance. This information is normally present, but it can be hard to extract if the antibody information is listed in a ‘Materials’ section and separated from descriptions of the techniques. Having the antibody data and application data closely linked would avoid potential confusion. Furthermore, if a study uses samples from more than one species then it is also important to clearly link which antibodies were used in which species.
There are other features that could also be reported which may be particularly relevant to certain studies. For example, the antibody batch number is rarely included in methods sections, but it is common to hear concern about variability between different antibody batches. This is often anecdotal, but there are some published examples9,10. This type of variability is likely to be a particular issue with polyclonal antibodies2, but may affect monoclonal antibodies11. We encourage scientists to report cases in which variability has been found and in these examples include batch numbers. Reporting the final antibody concentration or dilution is another piece of information which can help other researchers, especially if optimisation was required during the study.
It has been proposed that scientists should know the antigen which was used to raise the antibody3. There are exceptions, for example where antibodies have been raised from a cell/tissue lysate and the antigen is unknown, but for most cases the antigen or at least its location within the protein should be known, as it may have implications for interpretation of the results. In cases where it is relevant to the study authors should be encouraged to report the antigen location. Finally, there will be details of particular importance for individual techniques, we focus on research antibodies, but studies reporting therapeutic use would be an example in which specific details such as purity and dose need to be reported.
The Nature Publishing Group checklist, mentioned above, requires authors to demonstrate that every antibody used in their study has been validated for use in each of the specific experiments and species used. The experimental process of antibody validation is complex, with the most rigorous methods being comparison of wildtype vs a knockdown/knockout tissue and/or use of a second antibody to a different epitope. The validation must also be carried out for each experimental setup as specificity in one application, or even fixative, does not mean an antibody will be specific in another. It is also the case that the details that should be reported to demonstrate validation will be different for each application. For more information on antibody validation we highly recommend the following publications12–18.
Our focus is on how to report antibody validation, which can be achieved in a number of ways. If an antibody has not been previously validated for the specific combination of application and species used, then it should be mandatory that validation be carried out and reported. This can often be included as supplementary information.
If the antibody has previously been validated then one or more citations could be given to highlight the validation. Alternatively, the publication could reference the antibody validation profile from publicly available databases such as 1degreebio, Antibodypedia, CiteAb or pAbmAbs (A more extensive list of databases is available from Pivotal Scientific). Again it is important that antibody suppliers and codes are used in publications so that each antibody can be unambiguously identified and the degree of previous characterisation assessed. If new validation has been carried out then this could also be deposited in a public database and the database cited, instead of or in addition to putting the data in the supplementary information. Including information to show validation has occurred would help reviewers and other researchers accurately assess the results.
It seems likely that significant change is not going to occur unless journals take a lead and encourage it by adding antibody reporting guidelines to their instructions to authors. The success of this has been demonstrated by the Journal of Comparative Neurology which has had extensive guidelines in place since 2006 and the Journal of Visualised Experiments which requires a table of materials, including catalogue numbers for all the reagents used, to be reported. The Nature Publishing Group checklist should improve reporting in their journals and it is encouraging to see that following publication of version 1 of this manuscript F1000Research and PeerJ have added our proposed guidelines to their instructions for authors (described below). Once a journal has added guidelines it will be crucial that peer-reviewers are encouraged to evaluate the reporting and enforce the guidelines.
Based on the points discussed above we would suggest that journals adopt, and researchers use, the format shown in box 1.
Publications using commercial antibodies should report the supplier and the code number. Publications using academic antibodies should report the source laboratory and relevant reference. We recommend the following format;
“The following antibodies were used, Mouse anti-protein A monoclonal antibody (Company E, catalogue number #1000) was used for ELISA with human cells as validated in (figure X or reference Y or validation profile Z) and western blotting in mouse tissue as validated in (figure X or reference Y or validation profile Z).
This format is meant as a guide and could be adapted as required; for example details of batch number, dilution or epitope could be added where particularly important. This information could also be usefully presented in a table if allowed by the journal. Adoption of these reporting guidelines will not eliminate researchers’ frustrations with antibodies, but should help improve experimental reproducibility and scientists’ productivity, something we all seek. An additional benefit for authors who include this information is that well annotated publications are easier for antibody companies and antibody search engines to highlight in their databases. This inclusion is likely to increase the number of researchers who access their work and so potentially the impact of the study.
ADC conceived the idea behind the commentary and produced a draft manuscript. All authors were involved in the revision of the draft manuscript, production of a revised version 2 and have agreed to the final content.
ADC is a shareholder in CiteAb Ltd, which runs CiteAb the antibody search engine.
We thank everybody who commented on Version 1, in particular the reviewers for their helpful comments. We are also very grateful to Dr Mike Browning (PhosphoSolutions, USA) for suggesting some interesting references on antibody validation that are now included and Dr Leslie Boyer (University of Arizona) for her helpful comments regarding therapeutic antibodies.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (update) 23 Aug 13 |
read | read | |
Version 1 10 Jul 13 |
read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
That is an interesting observation; including catalogue codes is a big step forward in terms of being able to identify the reagents used, but I don't have any news ... Continue reading Dear Mark,
That is an interesting observation; including catalogue codes is a big step forward in terms of being able to identify the reagents used, but I don't have any news on their approach to whether validation information is required. It sounds like your observations suggests not.
That is an interesting observation; including catalogue codes is a big step forward in terms of being able to identify the reagents used, but I don't have any news on their approach to whether validation information is required. It sounds like your observations suggests not.